Characteristic | Group | |||
---|---|---|---|---|
Nodule positive | Endemic controls | Non-endemic controls | Lymphatic filariasis | |
No. of subjects | 98 | 50 | 18 | 51 |
Age, median (Min-Max) | 47 (21–85) | 35 (18–81) | 25 (13–52) | 33 (18–68) |
Gender, n (%) | ||||
Male | 53 (53) | 25 (50) | 12 (67) | 37 (73) |
Female | 45 (47) | 25 (40) | 6 (33) | 14 (27) |
No. of nodules, median (Min-Max) | 1 (1–5) | 0 | na | na |
mf status, n (%) | ||||
0 mf/mg | 87 (89) | 50 (100) | na | na |
0–5 mf/mg | 10 (9) | 0 (0) | na | na |
5–10 mf/mg | 1 (1) | 0 (0) | na | na |
No. of IVM rounds, median (Min-Max) | 2 (0–10) | 0 (0–1) | na | na |
Time since last ivermectin treatment, n (%) | na | |||
Not treated | 17 (17) | 33 (66) | na | na |
< 20 months | 67 (68) | 5 (10) | na | na |
> 20 months | 14 (14) | 12 (24) | na | na |
Ov16 status, n (%) | ||||
Positive | 68 (69) | 25 (50) | 0 (0) | 12 (24)a |
Negative | 30 (31) | 25 (50) | 18 (100) | 38 (75) |